Market revenue in 2023 | USD 59.1 million |
Market revenue in 2030 | USD 97.1 million |
Growth rate | 7.4% (CAGR from 2023 to 2030) |
Largest segment | Diagnostics |
Fastest growing segment | Therapeutics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Jubilant Pharmova, Nordion, Bracco, Iren SpA, Abliva AB, Lantheus Holdings Inc, Eckert & Ziegler Bebig SA, Mallinckrodt PLC Ordinary Shares - New, Cardinal Health Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nuclear medicine market will help companies and investors design strategic landscapes.
Diagnostics was the largest segment with a revenue share of 84.6% in 2023. Horizon Databook has segmented the Saudi Arabia nuclear medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia is one of the richest countries in GCC. The Ministry of Health in Saudi Arabia offers free treatment to government employees, Saudi nationals, and pilgrims. About 9.2 million expatriates in Saudi Arabia receive medical services from private hospitals.
Hospitals in Saudi Arabia are developing new nuclear medicines. For instance, in 2017, King Fahad Hospital in Jeddah received permission to practice nuclear medicine and its diagnostic radiology department received a license from the National Center for Radiation Protection for the use of radioactive substances in medical diagnosis & treatment.
The number of private hospitals in Saudi Arabia is expected to increase with the growing number of expatriates. In addition, the demand for radiopharmaceuticals is likely to increase in this country owing to factors such as rise in the number of private hospitals, increase in the per capita healthcare expenditure, and increased application of radiopharmaceuticals for diagnostic purposes.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia nuclear medicine market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia nuclear medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account